Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
epithelioid sarcoma from smarcb1 loss to therapeutic vulnerabilities
Original title: “Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.”
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
Original title: “Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies”